Karin Wernicke‐Panten

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo

Thomas Dirschka, Peter Radny, R. Dominicus et al. · British Journal of Dermatology · 2011 · 178 citations

Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide

K. Draeger, Karin Wernicke‐Panten, H.-J. Lomp et al. · Hormone and Metabolic Research · 1996 · 162 citations

Metabolic Syndrome, Higher Dosage, Diabetes Management +10

Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents with Type I Diabetes Mellitus

Ε. Schoenle, J. Van Dyk, Karin Wernicke‐Panten et al. · Journal of Pediatric Endocrinology and Metabolism · 2002 · 121 citations

Long‐term (6 and 12 months) follow‐up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF‐200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis

Thomas Dirschka, Peter Radny, R. Dominicus et al. · British Journal of Dermatology · 2012 · 98 citations · Full text

Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine—SORELLA 1 Study

Satish K. Garg, Karin Wernicke‐Panten, Maria Rojeski et al. · Diabetes Technology & Therapeutics · 2017 · 32 citations